Search research articles
Contact Us
Filters
Showing results (81-90 of 103) with videos related to
Page
of 11
Sort By:
Gynecologic Oncology
|
June 27, 2026
PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy
Laura M Chambers, Daniel Spakowicz, Julia Chalif, et al.
American Journal of Obstetrics and Gynecology
|
August 5, 2022
Less is more: clinical utility of postoperative laboratory testing following minimally invasive hysterectomy for endometrial cancer
Michelle D S Lightfoot, Ashley S Felix, Corinne A Calo, et al.
Gynecologic Oncology
|
July 15, 2026
Outcomes following complete response to immune checkpoint inhibitors in endometrial cancer
Reed M O'Connor, Julia Chalif, Anna Gonzalez, et al.
Gynecologic Oncology
|
April 10, 2023
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes
Monica D Levine, David A Barrington, Caitlin E Meade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2022
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial
Matthew A Powell, Virginia L Filiaci, Martee L Hensley, et al.
Gynecologic Oncology
|
May 27, 2026
Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma
Cassidy S Abdeen, Reed M O'Connor, Julia Chalif, et al.
Gynecologic Oncology
|
July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
Casey M Cosgrove, David E Cohn, Heather Hampel, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Gynecologic Oncology
|
October 16, 2022
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study
John K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 103) with videos related to
Sort By:
Page
of 11
Gynecologic Oncology
|
June 27, 2026
PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy
Laura M Chambers, Daniel Spakowicz, Julia Chalif, et al.
American Journal of Obstetrics and Gynecology
|
August 5, 2022
Less is more: clinical utility of postoperative laboratory testing following minimally invasive hysterectomy for endometrial cancer
Michelle D S Lightfoot, Ashley S Felix, Corinne A Calo, et al.
Gynecologic Oncology
|
July 15, 2026
Outcomes following complete response to immune checkpoint inhibitors in endometrial cancer
Reed M O'Connor, Julia Chalif, Anna Gonzalez, et al.
Gynecologic Oncology
|
April 10, 2023
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes
Monica D Levine, David A Barrington, Caitlin E Meade, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 10, 2022
Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial
Matthew A Powell, Virginia L Filiaci, Martee L Hensley, et al.
Gynecologic Oncology
|
May 27, 2026
Beyond extrapolation: Immunotherapy outcomes in recurrent vulvovaginal carcinoma
Cassidy S Abdeen, Reed M O'Connor, Julia Chalif, et al.
Gynecologic Oncology
|
July 16, 2017
Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival
Casey M Cosgrove, David E Cohn, Heather Hampel, et al.
Gynecologic Oncology
|
July 14, 2022
What proportion of patients with stage 3 ovarian cancer are potentially cured following intraperitoneal chemotherapy? Analysis of the long term (≥10 years) survivors in NRG/GOG randomized clinical trials of intraperitoneal and intravenous chemotherapy in stage III ovarian cancer
Omali Pitiyarachchi, Michael Friedlander, James J Java, et al.
Gynecologic Oncology
|
October 16, 2022
The clinical and prognostic significance of pre-chemotherapy serum CA-125 in high-risk early stage ovarian cancer: An NRG/GOG ancillary study
John K Chan, Chunqiao Tian, Joshua P Kesterson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
December 23, 2022
Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study
Alessandro D Santin, Ignace Vergote, Antonio González-Martín, et al.
Page
of 11